Testing Menu

Absolute Genomics is a high-complexity CLIA authorized laboratory that provides a wide variety of molecular diagnostic testing. The laboratory staff at Absolute Genomics is highly trained and experienced which is reflected by our seamless testing and customer service efforts. Molecular diagnosis of infectious disease is the focus and specialty of Absolute Genomics. To achieve this goal, we designed 5 panels: Wound InSITE, Nail InSITE, Respiratory InSITE, Urinary InSITE, STI InSITE, and Antibiotic Resistance (ABx Advantage). All of these panels are designed based on the epidemiological data from the CDC, NIH, and other established national organizations.

Individual pathogen targets selected for each panel went through several phases of data analysis and curation to establish contribution in disease causation. Relevant research articles and epidemiological databases are used as sources for selecting the pathogens that were most strongly related to a specific disease. Absolute Genomics prides itself on collecting and utilizing feedback from clients regarding the clinical relevance and diversity of pathogens on the panels. For example, the Absolute Genomics Respiratory InSITE panel is comprised of several viruses, bacterial ,and fungal targets. Within the genera, some of the pathogens are tested at the species level that gives more depth to the test. The ABx Advantage panel allows physicians to make better choices to treat drug resistance pathogens. The advantage with ABx Advantage panel is that it provides a single multi-potent drug choice as a treatment option. This superior technology relies on artificial intelligence, machine learning, and human expertise to provide doctors the best available treatment in a molecular test. When dealing with poly infection, doctors opt for multiple drugs. However, with Absolute Genomics stewardship they can confidently use a single antibiotic that would be effective against several pathogens. This is achieved by looking into multiple factors like site of infection, pathogens, detected resistance gene markets, drug induced allergies, age, and gender.

Individual pathogen targets selected for each panel went through several phases of data analysis and curation to establish contribution in disease causation. Relevant research articles and epidemiological databases are used as sources for selecting the pathogens that were most strongly related to a specific disease. Absolute Genomics prides itself on collecting and utilizing feedback from clients regarding the clinical relevance and diversity of pathogens on the panels. For example, the Absolute Genomics Respiratory InSITE panel is comprised of several viruses, bacterial and fungal targets. Within the genera, some of the pathogens are tested at the species level that gives more depth to the test. The ABx Advantage panel allows physicians to make better choices to treat drug resistance pathogens. The advantage with ABx Advantage panel is that it provides a single multi-potent drug choice as a treatment option. This superior technology relies on artificial intelligence, machine learning, and human expertise to provide doctors the best available treatment in a molecular test. When dealing with poly infection, doctors opt for multiple drugs. However, with Absolute Genomics stewardship they can confidently use a single antibiotic that would be effective against several pathogens. This is achieved by looking into multiple factors like site of infection, pathogens, detected resistance gene markets, drug induced allergies, age, and gender. Absolute Genomics is committed to innovation and excellence in molecular diagnostics. Currently, several research and development projects are being pursued ranging from metagenomics to germline next generation sequencing for genetic disorders.

Absolute Genomics is committed to innovation and excellence in molecular diagnostics. Currently, several research and development projects are being pursued ranging from metagenomics to germline next generation sequencing for genetic disorders.

- Dr. Ummar Raheel PhD, Director of Laboratory Operations

ABx Advantage

Sexual & Reproductive Health

ABx Advantage